Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 6:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–116 of 116 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Capsaicin Clear all
Completed No phase listed Observational Accepts healthy volunteers

The Effect of Bariatric Surgery on Peripheral Nerve Function and Axonal Regeneration

NCT02218866
View directory record Official record
Conditions
Peripheral Neuropathy, Obesity
Interventions
Not listed
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 80 Years
Enrollment
205 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 10, 2018 · Synced Oct 17, 2026, 6:02 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Dissecting the Heterogeneity of Oral Cancer Pain

NCT05024383
View directory record Official record
Conditions
Oral Squamous Cell Carcinoma
Interventions
Chemical sensitivity, Mechanical sensitivity
Other
Lead sponsor
NYU College of Dentistry
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Oct 17, 2026, 6:02 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Efficacy and Safety of a Single Application of Capsaicin 8%Transdermal Delivery System Compared to Placebo in Reducing Pain Intensity in Subjects With Painful Diabetic Peripheral Neuropathy (PDPN)

NCT01533428
View directory record Official record
Conditions
Diabetic Peripheral Neuropathy, Pain
Interventions
Capsaicin 8%, Placebo
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
369 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
29
States / cities
Anniston, Alabama • Fresno, California • Long Beach, California + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2015 · Synced Oct 17, 2026, 6:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of BL1332 on Capsaicin-Induced Ocular Pain in Healthy Trial Participants

NCT07717918
View directory record Official record
Conditions
Healthy
Interventions
BL1332 eye drops, BL1332 Placebo eye drops
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 17, 2026, 6:02 AM EDT
Completed Phase 2 Interventional

Pilot Study of High-Dose Capsaicin Patches to Treat Postherpetic Neuralgia Pain

NCT00034710
View directory record Official record
Conditions
Neuralgia, Pain, Peripheral Nervous System Diseases, Herpes Zoster
Interventions
Capsaicin Patch
Drug
Lead sponsor
NeurogesX
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002
U.S. locations
8
States / cities
Phoenix, Arizona • Tucson, Arizona • Naples, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2006 · Synced Oct 17, 2026, 6:02 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Nutraceutical Supplement With Standardized Botanicals in Males With Thinning Hair

NCT05339958
View directory record Official record
Conditions
Hair Thinning
Interventions
Nutrafol® Men Hair Growth Nutraceutical, Placebo Supplement
Dietary Supplement · Other
Lead sponsor
Nutraceutical Wellness Inc.
Industry
Eligibility
21 Years to 55 Years · Male only
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
2
States / cities
Manhattan Beach, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 1, 2023 · Synced Oct 17, 2026, 6:02 AM EDT
Completed Phase 2 Interventional Results available

The Qutenza Patch as Treatment for Disabling Treprostinil (Remodulin) Infusion Site Pain

NCT01260454
View directory record Official record
Conditions
Pulmonary Hypertension, Pulmonary Arterial Hypertension
Interventions
Qutenza (8% capsaicin)
Drug
Lead sponsor
University of Rochester
Other
Eligibility
15 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Apr 21, 2016 · Synced Oct 17, 2026, 6:02 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Efficacy and Safety of a Nutraceutical Supplement With Standardized Botanicals in Peri-menopausal and Menopausal Women With Thinning Hair

NCT04048031
View directory record Official record
Conditions
Hair Thinning
Interventions
Nutrafol Supplement Capsules, Placebo Capsules
Dietary Supplement · Other
Lead sponsor
Ablon Skin Institute Research Center
Other
Eligibility
40 Years to 65 Years · Female only
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Manhattan Beach, California
Source: ClinicalTrials.gov public record
Updated Apr 6, 2025 · Synced Oct 17, 2026, 6:02 AM EDT
Terminated Phase 2 Interventional

Efficacy and Safety Study of 4975 in Patients Undergoing Total Hip Replacement

NCT00683267
View directory record Official record
Conditions
Arthroplasty
Interventions
4975, highly purified capsaicin, Placebo
Drug
Lead sponsor
Anesiva, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
10
States / cities
Birmingham, Alabama • Arcadia, California • Glendale, California + 7 more
Source: ClinicalTrials.gov public record
Updated May 4, 2009 · Synced Oct 17, 2026, 6:02 AM EDT
Completed Not applicable Interventional Results available

Chest Pain Perception and Capsaicin Sensitivity in Patients With Acute Cardiac Ischemia

NCT02346916
View directory record Official record
Conditions
Chest Pain
Interventions
Capsaicin
Drug
Lead sponsor
Bassett Healthcare
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Cooperstown, New York
Source: ClinicalTrials.gov public record
Updated Mar 4, 2021 · Synced Oct 17, 2026, 6:02 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Periganglionic Resiniferatoxin for the Treatment of Intractable Pain Due to Cancer-induced Bone Pain

NCT02522611
View directory record Official record
Conditions
Intractable Pain, Palliative Care
Interventions
Resiniferatoxin
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 99 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 17, 2026, 6:02 AM EDT
Enrolling by invitation No phase listed Observational

Qutenza 8% Capsaicin Topical System for the Treatment of Neuropathic Axial Lower Back Pain and Lumbosacral Radiculopathy

NCT06540456
View directory record Official record
Conditions
Lower Back Pain, Lumbosacral Radiculopathy
Interventions
Qutenza® 8% Capsaicin Topical System
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Summerville, South Carolina
Source: ClinicalTrials.gov public record
Updated Mar 20, 2026 · Synced Oct 17, 2026, 6:02 AM EDT
Completed Early Phase 1 Interventional Results available

Assessment of Dystussia in Traumatic Brain Injury

NCT02240329
View directory record Official record
Conditions
TBI, Brain Injury
Interventions
Neuropsychological Testing and Measures of TBI severity, Respiratory measures, Capsaicin cough sensitivity testing
Behavioral · Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 60 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 28, 2015 · Synced Oct 17, 2026, 6:02 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Influence of Capsaicin Gel During Exercise Within the Heat

NCT05298202
View directory record Official record
Conditions
Acute Exercise, Heat Exposure
Interventions
Capsaicin, Control Gel, Exercise, Hot environment
Biological · Other
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 45 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Mar 15, 2024 · Synced Oct 17, 2026, 6:02 AM EDT
Active, not recruiting No phase listed Observational

Observational Study to Evaluate the Efficacy of Sustained QUTENZA® Use in Painful Diabetic Peripheral Neuropathy

NCT06495424
View directory record Official record
Conditions
Peripheral Diabetic Neuropathy, Painful Diabetic Neuropathy
Interventions
Capsaicin 8%
Drug
Lead sponsor
Averitas Pharma, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
10
States / cities
Wilmington, Delaware • Gainesville, Georgia • Jasper, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 17, 2026, 6:02 AM EDT
Completed Phase 2 Interventional

Tolerability of Three Local Anesthetic Formulations in Conjunction With NGX-4010 for the Treatment of Neuropathic Pain

NCT00082316
View directory record Official record
Conditions
Herpes Zoster, Neuralgia, Pain, HIV Infections, Peripheral Nervous System Diseases, Diabetic Neuropathies, Diabetes Mellitus, Polyneuropathies
Interventions
Capsaicin Dermal Patch
Drug
Lead sponsor
NeurogesX
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
17
States / cities
Huntsville, Alabama • Mobile, Alabama • Phoenix, Arizona + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2008 · Synced Oct 17, 2026, 6:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of Lidocaine Patch on Intradermal Capsaicin Induced Pain and Hyperalgesia

NCT00373893
View directory record Official record
Conditions
Pain, Hyperalgesia
Interventions
Lidoderm Patch
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Sep 8, 2006 · Synced Oct 17, 2026, 6:02 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Reduction in Pain Intensity Following IV or Oral Pain-relieving Products

NCT02678416
View directory record Official record
Conditions
Pain
Interventions
IV Acetaminophen (Treatment A), Oral Acetaminophen (Treatment B), Placebo (Treatment C), Morphine (Treatment D)
Drug · Other
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
79 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Oct 17, 2026, 6:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Clinical Adhesion Study Between ZTlido 1.8% and Three Over-the-counter External Analgesic Lidocaine-containing Patches

NCT05106400
View directory record Official record
Conditions
Healthy
Interventions
ZTlido (Lidocaine Topical System) 1.8%, Salonpas (Lidocaine Patch 4%), Aspercreme (Lidocaine Patch 4%), IcyHot (Lidocaine 4% + Menthol 1% Patch)
Drug
Lead sponsor
Scilex Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Dilworth, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Oct 17, 2026, 6:02 AM EDT
Terminated Phase 4 Interventional

Effects of Capsaicin on the Structure, Distribution, and Function of Cutaneous Small Nerve Fibers in Psoriatic Skin

NCT00697034
View directory record Official record
Conditions
Psoriasis
Interventions
Capsaicin
Drug
Lead sponsor
Wake Forest University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 13, 2018 · Synced Oct 17, 2026, 6:02 AM EDT